386 related articles for article (PubMed ID: 27649526)
1. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
3. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
4. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
5. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
6. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
7. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome.
Tessaris D; Matarazzo P; Lala R; Defabianis P
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):333-6. PubMed ID: 26565547
[TBL] [Abstract][Full Text] [Related]
8. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India.
Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N
Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.
Zhai X; Duan L; Yao Y; Xing B; Deng K; Wang L; Feng F; Liang Z; You H; Yang H; Lu L; Chen S; Wang R; Pan H; Zhu H
Front Endocrinol (Lausanne); 2021; 12():672394. PubMed ID: 34777239
[TBL] [Abstract][Full Text] [Related]
10. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.
Berglund JA; Tella SH; Tuthill KF; Kim L; Guthrie LC; Paul SM; Stanton R; Collins MT; Boyce AM
J Bone Miner Res; 2018 Sep; 33(9):1641-1648. PubMed ID: 29669167
[TBL] [Abstract][Full Text] [Related]
11. Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.
Hagelstein-Rotman M; Appelman-Dijkstra NM; Boyce AM; Chapurlat R; Dur NBJ; Gensburger D; Majoor BCJ; van de Sande MAJ; Dijkstra PDS
Calcif Tissue Int; 2022 Mar; 110(3):334-340. PubMed ID: 34854944
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome.
Yao Y; Liu Y; Wang L; Deng K; Yang H; Lu L; Feng F; Xing B; You H; Jin Z; Wang R; Pan H; Chen S; Zhu H
Eur J Endocrinol; 2017 Mar; 176(3):295-303. PubMed ID: 28007843
[TBL] [Abstract][Full Text] [Related]
14. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
[TBL] [Abstract][Full Text] [Related]
15. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.
Thomsen MD; Rejnmark L
Calcif Tissue Int; 2014 Apr; 94(4):384-95. PubMed ID: 24390518
[TBL] [Abstract][Full Text] [Related]
16. Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.
Geels RES; Meier ME; Saikali A; Tsonaka R; Appelman-Dijkstra NM; Boyce AM
J Bone Miner Res; 2022 Feb; 37(2):236-243. PubMed ID: 34668234
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark.
Meier ME; Vágó E; Abrahamsen B; Dekkers OM; Horváth-Puhó E; Rejnmark L; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2024 May; 109(6):1423-1432. PubMed ID: 38174586
[TBL] [Abstract][Full Text] [Related]
19. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
